Back to ESALY
Phase 2
Development Phase
0
Upcoming Catalysts
0
Historical Events
0
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
0 competitors in Platinum-Sensitive Ovarian Cancer in First Relapse
View Full LandscapeDrug Information
Target Indication
Platinum-Sensitive Ovarian Cancer in First Relapse
Clinical Trial
NCT02289950Last updated: 12/23/2025
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Drug Science
Mechanism of action & safety profile
Related Pipeline
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts